The era of CD19-directed therapy in diffuse large B-cell lymphoma
Abstract
In The Lancet Oncology, Paolo Caimi and colleagues 1 Caimi PF Ai W Alderuccio JP et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021; (published online May 11.)https://doi.org/10.1016/S1470-2045(21)00139-X Google Scholar report results of LOTIS-2, a phase 2 trial evaluating the CD19-directed antibody–drug conjugate loncastuximab...
Paper Details
Title
The era of CD19-directed therapy in diffuse large B-cell lymphoma
Published Date
Jun 1, 2021
Journal
Volume
22
Issue
6
Pages
741 - 742
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History